Key takeaways
Beyfortus (nirsevimab) and Arexvy (RSV vaccine) are both used to prevent respiratory syncytial virus (RSV) infections, but they are quite different in their approach and target populations. Beyfortus (nirsevimab) is a monoclonal antibody given as an injection to babies and children up to 24 months old to protect them from severe RSV illness. It is not a vaccine and works by providing ready-made antibodies that attach to the RSV virus, preventing it from spreading. Arexvy (RSV vaccine), on the other hand, is a recombinant protein vaccine for adults 60 years and older, and some younger adults at high risk. It helps your immune system make its own antibodies to fight RSV. Beyfortus is typically given once during the RSV season, while Arexvy is a one-time shot. Common side effects of Beyfortus include injection site reactions and rash, whereas Arexvy can cause tiredness, muscle pain, and more frequent injection site reactions. Both medications can be given with other vaccines, but Arexvy may cause more side effects when combined with other vaccines.
